The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

A microbial composition for improving the conditions in animal farms comprising: a slow-releasing carrier base having a first predetermined percentage by weight (w/w %); and a mixture of microorganisms identified in a 16S rRNA gene sequence so that the composition is capable of denitrification, feces decomposition, and hydrogen sulfide (H.sub.2S) oxidation.

The present disclosure provides materials and methods related to engineered bacteria for use in vaccines. In particular, the present disclosure provides novel compositions and methods for generating vaccine compositions comprising bacteria (e.g., Lactobacillus) engineered to express immunogenic polypeptides and immunogenicity-enhancing adjuvant polypeptides to treat and/or prevent infection from a pathogenic organism (e.g., coronavirus).

Disclosed herein is an isolated strain of Lactobacillus acidophilus TW01, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33990. Also disclosed herein are uses of the isolated strain of Lactobacillus acidophilus TW01 for alleviating an inflammation-related disorder and for improving gut health.

Microorganisms for lowering blood ammonia level and composition for protecting neuronal cells containing the same, particularly relates to microbes or a symbiotic pair that has a neuroprotective function by lowering blood ammonia levels or reducing ammonia levels in the body and composition for protecting neuronal cells comprising the microbes. The microorganisms having a neuroprotective function by lowering the blood ammonia level can be selected from the group that include, but not limited to, a Lactobacillus sp. strain and a Streptococcus sp. strain. The ammonia removal strains and the composition have a neuroprotective effect by their excellent ability to remove neurotoxic ammonia, and thus can be widely used as a preventive or therapeutic agent for hyperammonemia and neurological diseases caused thereby.

The present invention relates to a gene expression cassette including a strong promoter derived from lactic acid bacteria, and a gene expression vector including the same. According to the present invention, a large amount of a human protein, the physiological activity of which has been verified, may be stably produced with high efficiency by introducing a useful foreign gene into an expression vector and transforming probiotics with the expression vector. Through the production of this protein, it is possible to provide a basis for developing functional probiotics and making products using them.

Disclosed herein is an isolated strain of Lactobacillus acidophilus TW01, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33990. Also disclosed herein are use of the isolated strain of Lactobacillus acidophilus TW01 for alleviating an inflammation-related disorder and that for improving gut health.

A bacterial ferment obtained by a method including the following steps: (a) culturing Lactobacillus species in at least one growth medium for at least 24 hours; (b) separating the mixture via centrifugation; (c) adding lactic acid to the supernatant obtained from step b) in an amount sufficient to lower the pH value of the supernatant; (d) stabilizing the resulting mixture with the addition of at least one preservative and/or at least one multifunctional; and optionally (e) filtering the mixture to remove any final precipitation.

Disclosed herein is a method for promoting growth of a probiotic microorganism. The method includes cultivating the probiotic microorganism in a growth medium containing a fermented culture of lactic acid bacterial strains that include Lactobacillus salivarius subsp. salicinius AP-32 deposited at the China Center for Type Culture Collection (CCTCC) under CCTCC M 2011127, Lactobacillus plantarum LPL28 deposited at the China General Microbiological Culture Collection Center (CGMCC) under CGMCC 17954, Lactobacillus acidophilus TYCA06 deposited at the CGMCC under CGMCC 15210, and Bifidobacterium longum subsp. infantis BLI-02 deposited at the CGMCC under CGMCC 15212.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.